LRMR · Company research
Larimar Therapeutics, Inc. (LRMR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits | Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| $LRMR stock is down 15% today. Here's what we see in our data. - Quiver Quantitative | $LRMR stock is down 15% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 13, 2026 | neutral | 0 | 0.6 |
| Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits | Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - Stocktwits | LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns Stocktwits | View source ↗ | Stocktwits | Oct 10, 2026 | neutral | 0 | 0.6 |
| 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead - MarketBeat | 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead MarketBeat | View source ↗ | MarketBeat | Oct 10, 2026 | neutral | 0 | 0.6 |
| Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner | Larimar stock has declined 22.7% over the past four weeks and is now in oversold territory with an RSI reading of 28.31, suggesting a potential trend reversal. Analysts have raised earnings estimates by 5% over the last 30 days, and the stock holds a Zacks Rank #2 (Buy) rating, indicating potential near-term price appreciation. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 1 | 1 |
| Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance UK | Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 5, 2026 | neutral | 0 | 0.6 |
| A new executive gets the right to buy 800,000 Larimar shares - Stock Titan | A new executive gets the right to buy 800,000 Larimar shares Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Larimar Therapeutics (NasdaqGM:LRMR) Stock Forecast & Analyst Predictions - Simply Wall Street | Larimar Therapeutics (NasdaqGM:LRMR) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 28, 2026 | neutral | 0 | 0.6 |
| $LRMR stock is down 9% today. Here's what we see in our data. - Quiver Quantitative | $LRMR stock is down 9% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 24, 2026 | neutral | 0 | 0.6 |
| LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 - Yahoo Finance | LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 Yahoo Finance | View source ↗ | Yahoo Finance | Jul 8, 2026 | neutral | 0 | 0.6 |
| Larimar Therapeutics: Late-Stage FA Program Advances Amid Execution Risks (NASDAQ:LRMR) - Seeking Alpha | Larimar Therapeutics: Late-Stage FA Program Advances Amid Execution Risks (NASDAQ:LRMR) Seeking Alpha | View source ↗ | Seeking Alpha | Jun 30, 2026 | neutral | 0 | 0.6 |
| LRMR Stock Holds Support As Biotech Traders Watch Cash Runway - Timothy Sykes | LRMR Stock Holds Support As Biotech Traders Watch Cash Runway Timothy Sykes | View source ↗ | Timothy Sykes | Jun 29, 2026 | neutral | 0 | 0.6 |
| LRMR Stock Dips As Traders Weigh Cash Runway And Volatility - StocksToTrade | LRMR Stock Dips As Traders Weigh Cash Runway And Volatility StocksToTrade | View source ↗ | StocksToTrade | Jun 29, 2026 | neutral | 0 | 0.6 |
| Larimar says FDA can review nomlabofusp for accelerated approval - Stock Titan | Larimar says FDA can review nomlabofusp for accelerated approval Stock Titan | View source ↗ | Stock Titan | Jun 29, 2026 | neutral | 0 | 0.6 |
| Larimar Therapeutics stock tumbles after clinical data release - Investing.com | Larimar Therapeutics stock tumbles after clinical data release Investing.com | View source ↗ | Investing.com | Jun 29, 2026 | neutral | 0 | 0.6 |
| LRMR Forecast — Price Target — Prediction for 2027 - TradingView | LRMR Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.